CIK 1844645
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
| Name | Title (as filed) | Since | Ownership |
|---|---|---|---|
| PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD FE GENERAL PARTNER OF PIVOTAL BIOVENTURE PARTNERS FUND | G.P., L.P. | 2016-12 | 75%+ ·◆ |
| BISGAARD, PETER, TUXEN | MANAGING DIRECTOR | 2022-06 | <5% ·◆ |
| HOPFNER, ROBERT, LORNE | MANAGING DIRECTOR | 2017-12 | <5% ·◆ |
| TRAVERS, MICHAEL, LAWRENCE | US CHIEF OPERATING OFFICER AND GENERAL COUNSEL | 2022-08 | <5% ·◆ |
| TSE, BRIAN, KIN KWOK | OFFICER | 2018-03 | <5% |
| PIVOTAL PARTNERS LTDentity | OWNER OF PIVOTAL BIOVENTURE PARTNERS FUND II G.P. LTD | 2016-12 | 75%+ ·◆ |
Direct owners and executive officers as filed on the adviser's Form ADV Schedule A (as-filed titles; ADV updates annually and on material change). This lists officers and 5%+ owners — not necessarily the full portfolio-management team.
Signed this manager's latest 13F (2026-Q1). The filing's authorized signatory — frequently a compliance officer, general counsel, or CFO — not necessarily the portfolio manager or firm leadership.
